A kemoterápia okozta hányás csillapítása

Research output: Article

2 Citations (Scopus)


Chemotherapy-induced vomiting and nausea is the most common adverse event of anticancer therapy. In different guide-lines (MASCC, NCCN, ESMO and ASCO) antiemetic prophylaxis is directed toward the emetogenic potential of the chemotherapy and the type of vomiting and nausea. Chemotherapeutic agents are classified into four emetic risk groups: high, moderate, low, and minimal. Steroids, dexamethasone, metoclopramide, cannabinoids, benzodiazepines, 5-HT3 receptor antagonists (ondansetron, granisetron, tropisetron) and a new group of antiemetics, the neurokinin1 receptor antagonists are used to prevent anticipatory, acute and delayed vomiting and nausea. This paper examines evidence-based recommendations for optimal use of antiemetics.

Translated title of the contributionProphylaxis of chemotherapy-induced vomiting and nausea
Original languageHungarian
Pages (from-to)391-394
Number of pages4
JournalMagyar onkologia
Issue number4
Publication statusPublished - dec. 1 2008


  • 5-HT3 receptor antagonists
  • Chemotherapy-induced vomiting and nausea

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'A kemoterápia okozta hányás csillapítása'. Together they form a unique fingerprint.

  • Cite this